Alder BioPharmaceuticals, Inc. announced the appointment of Paul Streck, M.D., as chief medical officer, effective January 21, 2019. He will report to Bob Azelby, company's president and chief executive officer. Dr. Streck brings more than 25 years of experience in drug development, regulatory and medical affairs leadership across both large and small publicly traded biopharmaceutical companies. He joins Alder from Insmed Incorporated, where he served as chief medical officer and played an instrumental role as a member of the executive leadership team, successfully leading the Arikayce regulatory filing, approval and launch. Prior to Insmed, Dr. Streck was GlaxoSmithKline plc’s group vice president and global medical lead of the Immuno-inflammation division responsible for the immunology portfolio strategy, including Benlysta and sirukumab.